These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
278 related articles for article (PubMed ID: 18794797)
1. Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor. Wykosky J; Palma E; Gibo DM; Ringler S; Turner CP; Debinski W Oncogene; 2008 Dec; 27(58):7260-73. PubMed ID: 18794797 [TBL] [Abstract][Full Text] [Related]
2. EphA2 as a novel molecular marker and target in glioblastoma multiforme. Wykosky J; Gibo DM; Stanton C; Debinski W Mol Cancer Res; 2005 Oct; 3(10):541-51. PubMed ID: 16254188 [TBL] [Abstract][Full Text] [Related]
3. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Wykosky J; Debinski W Mol Cancer Res; 2008 Dec; 6(12):1795-806. PubMed ID: 19074825 [TBL] [Abstract][Full Text] [Related]
4. EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model. Tandon M; Vemula SV; Sharma A; Ahi YS; Mittal S; Bangari DS; Mittal SK J Gene Med; 2012 Feb; 14(2):77-89. PubMed ID: 22228563 [TBL] [Abstract][Full Text] [Related]
5. Up-regulation of EphA2 and down-regulation of EphrinA1 are associated with the aggressive phenotype and poor prognosis of malignant glioma. Li X; Wang L; Gu JW; Li B; Liu WP; Wang YG; Zhang X; Zhen HN; Fei Z Tumour Biol; 2010 Oct; 31(5):477-88. PubMed ID: 20571968 [TBL] [Abstract][Full Text] [Related]
6. A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells. Wykosky J; Gibo DM; Debinski W Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3208-18. PubMed ID: 18089715 [TBL] [Abstract][Full Text] [Related]
7. The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas. Binda E; Visioli A; Giani F; Lamorte G; Copetti M; Pitter KL; Huse JT; Cajola L; Zanetti N; DiMeco F; De Filippis L; Mangiola A; Maira G; Anile C; De Bonis P; Reynolds BA; Pasquale EB; Vescovi AL Cancer Cell; 2012 Dec; 22(6):765-80. PubMed ID: 23238013 [TBL] [Abstract][Full Text] [Related]
9. Receptor EphA2 activation with ephrinA1 suppresses growth of malignant mesothelioma (MM). Nasreen N; Mohammed KA; Lai Y; Antony VB Cancer Lett; 2007 Dec; 258(2):215-22. PubMed ID: 17949899 [TBL] [Abstract][Full Text] [Related]
10. The Expression of ephrinA1/ephA2 Receptor Increases in Chronic Rhinosinusitis and ephrinA1/ephA2 Signaling Affects Rhinovirus-Induced Innate Immunity in Human Sinonasal Epithelial Cells. Lee SH; Kang SH; Han MS; Kwak JW; Kim HG; Lee TH; Lee DB; Kim TH Front Immunol; 2021; 12():793517. PubMed ID: 34975898 [TBL] [Abstract][Full Text] [Related]
11. Spatial organization of EphA2 at the cell-cell interface modulates trans-endocytosis of ephrinA1. Greene AC; Lord SJ; Tian A; Rhodes C; Kai H; Groves JT Biophys J; 2014 May; 106(10):2196-205. PubMed ID: 24853748 [TBL] [Abstract][Full Text] [Related]
12. Bidirectional signalling between EphA2 and ephrinA1 increases tubular cell attachment, laminin secretion and modulates erythropoietin expression after renal hypoxic injury. Rodriguez S; Rudloff S; Koenig KF; Karthik S; Hoogewijs D; Huynh-Do U Pflugers Arch; 2016 Aug; 468(8):1433-48. PubMed ID: 27228995 [TBL] [Abstract][Full Text] [Related]
13. Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1. Noblitt LW; Bangari DS; Shukla S; Knapp DW; Mohammed S; Kinch MS; Mittal SK Cancer Gene Ther; 2004 Nov; 11(11):757-66. PubMed ID: 15359289 [TBL] [Abstract][Full Text] [Related]
14. EphrinA1 is released in three forms from cancer cells by matrix metalloproteases. Beauchamp A; Lively MO; Mintz A; Gibo D; Wykosky J; Debinski W Mol Cell Biol; 2012 Aug; 32(16):3253-64. PubMed ID: 22688511 [TBL] [Abstract][Full Text] [Related]
15. Biological and structural characterization of glycosylation on ephrin-A1, a preferred ligand for EphA2 receptor tyrosine kinase. Ferluga S; Hantgan R; Goldgur Y; Himanen JP; Nikolov DB; Debinski W J Biol Chem; 2013 Jun; 288(25):18448-57. PubMed ID: 23661698 [TBL] [Abstract][Full Text] [Related]
16. Spatially modulated ephrinA1:EphA2 signaling increases local contractility and global focal adhesion dynamics to promote cell motility. Chen Z; Oh D; Biswas KH; Yu CH; Zaidel-Bar R; Groves JT Proc Natl Acad Sci U S A; 2018 Jun; 115(25):E5696-E5705. PubMed ID: 29866846 [TBL] [Abstract][Full Text] [Related]
17. EphA2 receptor activation by monomeric Ephrin-A1 on supported membranes. Xu Q; Lin WC; Petit RS; Groves JT Biophys J; 2011 Dec; 101(11):2731-9. PubMed ID: 22261062 [TBL] [Abstract][Full Text] [Related]
18. Ephrin-A1 inhibits NSCLC tumor growth via induction of Cdx-2 a tumor suppressor gene. Sukka-Ganesh B; Mohammed KA; Kaye F; Goldberg EP; Nasreen N BMC Cancer; 2012 Jul; 12():309. PubMed ID: 22824143 [TBL] [Abstract][Full Text] [Related]
19. [Expressions of angiogenesis-related factors: CD105, EphA2 and EphrinA1 in laryngeal squamous cell carcinoma and clinical implication]. Su J; Ji XB; Xie JH; Li W Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Dec; 51(12):929-936. PubMed ID: 27978884 [No Abstract] [Full Text] [Related]